Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Bio-Rad Laboratories ( (BIO) ) is now available.
On August 26, 2025, Bio-Rad Laboratories hosted an informational webinar on its Droplet Digital PCR product portfolio, highlighting the technology’s precision and scalability. The event, led by company executives, aimed to showcase Bio-Rad’s leadership in digital PCR and its potential to drive future growth by transitioning customers from traditional PCR methods to its advanced digital solutions.
The most recent analyst rating on (BIO) stock is a Buy with a $336.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.
Spark’s Take on BIO Stock
According to Spark, TipRanks’ AI Analyst, BIO is a Outperform.
Bio-Rad Laboratories’ overall stock score is driven by strong earnings call performance and positive technical indicators. Financial performance shows recovery, but valuation concerns and inconsistent revenue growth temper the score. Strategic acquisitions and leadership changes support a positive outlook.
To see Spark’s full report on BIO stock, click here.
More about Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. operates in the life sciences and clinical diagnostics industry, providing innovative products and solutions such as Droplet Digital PCR technology, which is used for precise nucleic acid quantification and has applications in biopharma, oncology, and diagnostics.
Average Trading Volume: 349,421
Technical Sentiment Signal: Hold
Current Market Cap: $8.04B
See more insights into BIO stock on TipRanks’ Stock Analysis page.